30989-81-2

Usage

Uses

Used in Pharmaceutical Synthesis:
3-Amino-2-methylacrylaldehyde is utilized as a key intermediate for the synthesis of pharmaceuticals, given its ability to contribute to the development of a broad spectrum of medicinal compounds.
Used in Agrochemical Production:
In the agrochemical industry, 3-Amino-2-methylacrylaldehyde is employed as a vital component in the creation of various agrochemicals, enhancing crop protection and management solutions.
Used in Fine Chemicals Manufacturing:
3-Amino-2-methylacrylaldehyde is used as a fundamental building block in the production of fine chemicals, where its reactivity and versatility are harnessed to produce high-quality specialty chemicals.
Used in Resin and Polymer Production:
AMA is leveraged as a crucial precursor in the synthesis of resins and polymers, contributing to the development of materials with specific properties for various applications.
Used in Organic Synthesis:
3-Amino-2-methylacrylaldehyde is used as a versatile reactant in organic synthesis, enabling the formation of a wide range of organic compounds with different functional groups.
Used in Drug Development:
Due to its antimicrobial and anti-inflammatory properties, 3-Amino-2-methylacrylaldehyde is applied in the development of new drugs and pharmaceuticals, offering potential therapeutic benefits in treating infections and inflammatory conditions.

InChI:InChI=1/C4H7NO/c1-4(2-5)3-6/h2-3H,5H2,1H3/b4-2+

Upstream product

• 42588-57-8 3-ethoxymethacrolein 

Downstream Products

• 85147-10-0 2,4-Diamino-6-methylpyrido<2,3-d>pyrimidine 
• 930272-56-3 2-(tert-butoxycarbonyl-aminomethyl)-5-methylpyrimidine 
• 7554-65-6 4-methyl-1H-pyrazole 
• 2036-41-1 5-methylpyrimidine 

Relevant academic research and scientific papers

BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT

This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with CNS disorders. It also relates to the use of an α5-containing GABAA receptor agonist (e.g., an α5-containing GABAA receptor positive allosteric modulator) in treating cognitive impairment associated with CNS disorders in a subject in need or at risk thereof, including age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI, Age-Associated Memory Impairment, Age Related Cognitive Decline, dementia, Alzheimer's Disease(AD), prodromal AD, PTSD, schizophrenia, bipolar disorder, ALS, cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease, autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction. It also relates to the use of an α5-containing GABAA receptor agonist (e.g., an α5-containing GABAA receptor positive allosteric modulator) in treating brain cancers (including brain tumors, e.g., medulloblastomas), and cognitive impairment associated therewith.

BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT

This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a α5-containing GABAA receptor agonist (e.g., a α5-containing GABAA receptor positive allosteric modulator) as described herein in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease(AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction. It also relates to the use of a α5-containing GABAA receptor agonist (e.g., a α5-containing GABAA receptor positive allosteric modulator) as described herein in treating brain cancers (including brain tumors, e.g., medulloblastomas), and cognitive impairment associated therewith.

A N - 2 - pyridyl -5 - pyrimidine preparation of method (by machine translation)

The invention relates to a pesticide in the technical field, and discloses a N - 2 - pyridyl - 5 - pyrimidine preparation of method, comprises the following steps: the 3 - ethoxy - 2 - methyl acrolein with ammonia ammoniation reaction to produce 3 - amino - 2 - methacrolein, the quality of the ammonia concentration is 20 - 25%, the 3 - ethoxy - 2 - methyl acrolein and ammonia in a molar ratio of 1: 1.0 - 1.5: 1.0 - 6.0. The N - 2 - pyridyl - 5 - pyrimidine preparation of method, by 3 - ethoxy - 2 - methyl acrolein as the starting material, through the ammoniation, cyclizes and brominated to obtain 5 - bromo methyl pyrimidine, then with 2 - aminopyridine reaction to obtain the target product, this invention adopts the cheap and easy to obtain 3 - ethoxy acrolein, in conventional process compared with the use of expensive 5 - pyrimidine formaldehyde, and greatly reduces the production cost, at the same time the invention the preparation method has the advantage of high yield, low cost, high efficiency in the production of more, in low-cost cases can prepare more N - 2 - pyridyl - 5 - pyrimidine methylamine, high practicability. (by machine translation)

BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT

This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a α5- containing GABAA receptor agonist (e.g., a α5-containing GABAA receptor positive allosteric modulator) as described herein in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age- Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer' s Disease(AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson' s disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction.

BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT

This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a a5- containing GABAA receptor agonist (e.g., a α5 -containing GABAA receptor positive allosteric modulator) as described herein in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease(AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction.